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Micro-abstract
-30% of patients with advanced NSCLC are refractory to platinum-based chemotherapy -We investigated the role of the Sonic Hedgehog (Shh)pathway in these rpatients -R-patients had a higher Gli2 expression than other patients -Gli2 expression was independently correlated with PFS and OS -Shh pathway inhibition had a synergistic effect in vitro with cisplatin M A N U S C R I P T
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Introduction
Despite the progress made in oncogenic driver identification, most advanced nonsmall cell lung cancers (NSCLCs) are treated with first-line cytotoxic platinum-based chemotherapy. According to the majority of randomized Phase III trials, approximately 25% to 30% of patients exhibit early disease progression under chemotherapy and are called refractory patients (r-patients) [1] [2] [3] [4] [5] [6] [7] [8] [9] . We previously described the characteristics of r-patients [10] . The only factor independently correlated to early progression was the sarcomatoid subtype. In another study, nearly 70% of patients with advanced sarcomatoid carcinoma exhibited early progression with chemotherapy [11] . Numerous predictive factors of resistance to platinum-based chemotherapy have been extensively studied in NSCLC, yet the majority involved early-stage NSCLC treated with surgery due to the availability of tumor tissue.
ERCC1 (Excision Repair Cross-Complementary group 1) is a protein involved in DNA
repair. Its predictive role of adjuvant chemotherapy benefit in early-stage NSCLC has already been demonstrated [12] , although its impact on chemoresistance in advanced-stage disease is more debatable [13, 14] . A Phase II trial has demonstrated the feasibility of a personalized adjuvant treatment according to epidermal growth factor receptor (EGFR) and ERCC1 status [15] . However, the antibody used for
ERCC1 expression in immunohistochemistry (IHC) is not reliable, and ERCC1
expression testing in IHC is no longer recommended [16] . BRCA1 (Breast Cancer 1)
is another protein involved in DNA repair. Despite encouraging preliminary data on its impact on chemoresistance prediction in advanced-stage NSCLC [17, 18] , a recent phase III trial testing customized chemotherapy according to BRCA1 level was reported as negative [19] . There is therefore an urgent need to validate new predictive markers.
The role of cancer stem cells (CSCs) in chemoresistance has previously been suggested [20] . CSCs constitute a small undifferentiated tumor cell contingent, chemoresistant and responsible for cancer relapse and metastatic spreading. Some specific pathways are overexpressed in CSCs, such as the Sonic Hedgehog (Shh)
pathway. Shh pathway overexpression has been demonstrated in small-cell lung cancer (SCLC) and NSCLC [21] [22] [23] [24] [25] . The final downstream factor in the Shh pathway is the Gli protein family, primarily Gli1 and Gli2, responsible for gene transcription. In this study, we analyzed the role of Shh pathway activation in advanced NSCLC refractory to first-line platinum-based chemotherapy.
Patients and methods
Patients and tumor samples
We retrospectively reviewed all consecutive patients treated in our department with Demographic, histological, and treatment data were recorded. All patients were evaluated for tumor response after three cycles of treatment by means of clinical examination, chest X-ray, and chest and upper-abdomen computed tomography scan, conducted by dedicated radiologists specialized in thoracic oncology. At that M A N U S C R I P T A C C E P T E D 
Immunohistochemistry (IHC)
We used the anti-rabbit Gli1 (sc-20687, 1:75, Santa Cruz) and anti-rabbit Gli2 (ab- 
The anaplastic lymphoma kinase (ALK)-fusion transcript was investigated by IHC on 4-µM slides from paraffin-embedded tissue using a monoclonal mouse antibody (5A4) (Abcam, UK) on a Benchmark system (Ventana Medical System, USA), according to the manufacturer's instructions [28] . Staining was quantified as the percentage of positive cells (0-100%) with an intensity ranging from 0 (no staining) to 3 (strong staining). A 10% positivity of cells with an intensity ≥2 defined positive staining, as reported by Yi et al. [29] .
Cultures and MTT assays
Primary cultures were obtained from tumors from four sarcomatoid carcinoma 
Ethical considerations
Each patient signed a research-approval form according to national guidelines, 
Statistical analyses
Comparisons of categorical variables between the r-and c-patients were performed using the chi-squared test, whereas comparisons between continuous variables were conducted using the Mann-Whitney test. Continuous variables were expressed as mean ± standard deviation (SD) for normal distributions or median + interquartile range (IQR) for non-normal distributions. PFS and survival were evaluated using the Kaplan-Meyer method (log-rank test), and were expressed as median ± IQR. The censoring date was 07/02/2014. Multivariate analysis was performed using a logistical regression model and included all variables that produced a p-value <0.25 in the univariate comparison between r-and c-patients. The combinatorial effects of treatments were quantified using the Chou-Talalay method to obtain the Combination Index (CI), where CI <1, =1, and >1 represented synergism, additive effect, and
antagonism, respectively [30] . The correlation between the IC50 of cisplatin and the CI was assessed using Spearman's rank-order correlation test. P-values <0.05 were considered statistically significant. Statistical analyses were carried out using Xlstat 2014 software (Addinsoft®, France). been published [11] . Of these 178 patients, 36 had surgical pathological samples available for analysis. The demographic data has been summarized in Table 1 Figure 1C ). Gli2 positive score was more frequent in the rpatients than in c-patients (41.7% versus 8.3%, respectively; p=0.02) ( Figure 1D ).
Results
r-patients exhibited higher Gli2 expression than c-patients
The characteristics of Gli2-positive patients have been summarized in Table 2 71.4% of the Gli2-positive samples were also Gli1-positive.
Patients with Gli2-positive tumors had shorter PFS and shorter OS compared to c-patients
Gli1-positive score had no impact on PFS or OS (Figure 2A 
Inhibition of the Shh pathway sensitized chemoresistant CBNPC cells in vitro
We used NSCLC cell lines (H322 and AA549) and primary cell lines of sarcomatoid carcinomas (n=4), treated in vitro by cisplatin. As expected, the H322 and A549 cell lines were more chemosensitive (IC50 of 27µM and 56µM, respectively), than the four sarcomatoid primary cell cultures (IC50 of 67µM, 75µM, 100µM, and 500µM).
Inhibition of Shh pathway, using smoothened (SMO) receptor inhibitor vismodegib, induced minimal cytotoxic effect on the six different cell lines. As shown in Figure 3A , concomitant treatment with cisplatin and vismodegib induced a synergistic cytotoxic effect in the three most resistant sarcomatoid primary cultures, demonstrated by the resulting CI <1, and had no synergistic effect on either the most chemosensitive sarcomatoid primary culture (with the IC50 for cisplatin found to be similar to IC50 of A549) or the two NSCLC cell lines. There was also a significant correlation between the IC50 of cisplatin and the CI, suggesting that vismodegib benefit is higher in the most chemoresistant cells ( Figure 3B ).
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Discussion
We found that the Shh pathway was activated in advanced NSCLC, with expression of Gli1 and Gli2 in 31.4% and 41.7% of tumor samples, respectively. Moreover, a Gli2-positive score was associated with chemoresistance. R-patients more often exhibited a Gli2-positive score compared to the c-patients, and a Gli2-positive score was found to be an independent factor of poor PFS and poor OS in multivariate Shh activation and epithelial-mesenchymal transition in squamous-cell lung carcinomas [35] .
We found that Gli2 has an impact on prognosis in advanced NSCLC. Previous studies have suggested that Gli1 expression has a prognostic capacity in early-stage NSCLC. While Yue et al. found that Gli1 expression was inversely correlated with disease-free survival in early-stage squamous-cell carcinoma [35] , they did not test Gli2 expression in this study. Little is known about the transcriptional activity differences between Gli1 and Gli2, Both Gli1 and Gli2 are known to have the same promoter-binding site [36] , yet Gli1 is expressed secondarily, induced by Gli2 [37, 38] .
Nevertheless, these findings result from studies conducted in developmental steps or M A N U S C R I P T
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in normal tissue, not in solid tumors. The majority of NSCLC studies have used Gli1, not Gli2, as the surrogate marker of the Shh pathway. As we found that Gli2, had an impact on PFS or OS, and not Gli1, some differences may exist between these two proteins in NSCLC, and further studies are therefore required.
We found that the inhibition of the Shh pathway by vismodegib sensitized tumor cells to cisplatin treatment. Tian et al. published similar results, with lower cell survival rates in vitro with combined vismodegib and cisplatin therapy compared to using either alone in HCC cell line [39] , yet no synergistic score was used. Other studies have already reported vismodegib to be efficient in cisplatin-resistant lung-cancer cells [38, 39] , although these results were based on a single NSCLC cell line (H1399 or A549). Interestingly, the same results were found in malignant pleural mesothelioma, with a synergistic effect observed with vismodegib and pemetrexed [40] . Vismodegib has been tested in a phase II trial in unselected advanced small-cell lung carcinoma, in addition with platinum -etoposide chemotherapy in first line, with negative results (Eastern Cooperative Oncology Group ECOG-1508 trial) [41] .
However, no published data are available to date with vismodegib in advanced NSCLC. Shh inhibition in NSCLC with vismodegib is challenging, because of possible non-canonical Gli activation mechanisms. However, some papers have suggested that, in NSCLC, the canonical Shh activation pathway, through Smo activation, is the predominant mechanism [35] .
Our study displayed several limitations. First, this was a retrospective study, involving a small number of patients. In addition, we only studied samples from surgical procedures. However, this cohort was found to be representative of the general population, as there was no statistical difference concerning the demographic data (gender, smoker status, or histological type) between this surgical cohort and the M A N U S C R I P T
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14 entire cohort, except for age. The patients who underwent surgery were younger than the patients from the general cohort, probably due to a selection bias for surgery.
Finally, further experiments are needed to validate the Gli2 IHC score and its prognosis impact in a larger prospective validation cohort, including small-size biopsies.
In conclusion, Shh pathway activation appears to play a critical role in terms of chemoresistance and prognosis. Furthermore, the benefits of Shh pathway inhibition are even greater in chemoresistant NSCLC. Targeted Shh therapies should now be investigated and evaluated through clinical studies in NSCLC r-patients.
Clinical practice points
Chemoresistance is a major challenge in the treatment of advanced NSCLC, and 30% of patients with advanced NSCLC will experience progression with platinumbased first-line treatment. We found that the Shh pathway was activated in advanced NSCLC, and that the expression of Gli2 was associated with chemoresistance. A Gli2-positive score was found to be an independent factor of poor PFS and poor OS in multivariate analysis. In vitro studies confirmed that the inhibition of the Shh Gli1-positive score Gli1-negative score Gli2-positive score Gli2-negative score A B
